Loading...

Chalice Brands Ltd.

CHAL.CNCNQ
Healthcare
Drug Manufacturers - Specialty & Generic
CA$0.23
CA$0.00(0.00%)

Chalice Brands Ltd. CHAL.CN Peers

See (CHAL.CN) competitors and their performances in Stock Market.

Peer Comparison Table: Drug Manufacturers - Specialty & Generic Industry

Detailed financial metrics including price, market cap, P/E ratio, and more.

SymbolPriceChange %Market CapP/E RatioEPSDividend Yield
CHAL.CNCA$0.23N/A14.7M-2.25-CA$0.10N/A
CURA.CNCA$5.22+9.21%4.1B-6.07-CA$0.86N/A
BHC.TOCA$8.13+8.40%3B-47.82-CA$0.17N/A
VRNO.CNCA$6.32+6.76%2.2B-5.40-CA$1.17N/A
GTII.CNCA$6.71-1.47%1.6B23.96CA$0.28N/A
CRON.TOCA$2.63-2.23%1B13.84CA$0.19N/A
TRUL.CNCA$4.96-2.94%929.3M-4.55-CA$1.09N/A
CURA.TOCA$1.09-1.80%847.2M-2.53-CA$0.43N/A
TER.CNCA$2.38-0.42%804.8M-1.33-CA$1.79N/A
DHT-UN.TOCA$13.33+0.30%750.6M333.25CA$0.04+3.90%
Showing 1 to 10 of 100 results
1

Stock Comparison

Select a stock to compare (requires JavaScript). Showing default comparison.

CHAL.CN vs CURA.CN Comparison

CHAL.CN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, CHAL.CN stands at 14.7M. In comparison, CURA.CN has a market cap of 4.1B. Regarding current trading prices, CHAL.CN is priced at CA$0.23, while CURA.CN trades at CA$5.22.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

CHAL.CN currently has a P/E ratio of -2.25, whereas CURA.CN's P/E ratio is -6.07. In terms of profitability, CHAL.CN's ROE is +0.00%, compared to CURA.CN's ROE of -0.25%. Regarding short-term risk, CHAL.CN is less volatile compared to CURA.CN. This indicates potentially lower risk in terms of short-term price fluctuations for CHAL.CN.

Stock Price Comparison

Loading...

Frequently Asked Questions